A11 Blockade of Myeloid Suppressor Cells Overcomes the Anti-PD-1/PD-L1 Resistance in KRAS-Driven and LKB1-Deficient NSCLC
R. Li(UCLA Health), Steven M. Dubinett(University of California, Los Angeles), Jingtian Zhe(UCLA Health), Ziling Huang(UCLA Health), Raymond J. Lim(University of California, Los Angeles), S. Ong(University of California, Los Angeles), Michael A. Teitell(University of California, Los Angeles), John D. Minna(The University of Texas Southwestern Medical Center), Ramin Salehi‐Rad(University of California, Los Angeles), Linh M. Tran(University of California, Los Angeles), Kostyantyn Krysan(University of California, Los Angeles), Beiyun Liu(Beijing University of Technology), David B. Shackelford(University of California, Los Angeles), Milica Momcilovic(Columbia University), Manash K. Paul(University of California, Los Angeles)
Cited by 1
Related Papers
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer
|The EMBO Journal|2014|466
Mammalian TAK1 Activates Snf1 Protein Kinase in Yeast and Phosphorylates AMP-activated Protein Kinase in Vitro
|Journal of Biological Chemistry|2006|461